EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognostic Value of the Geriatric Nutritional Risk Index in Previously Untreated Patients with Advanced Non-Small Cell Lung Cancer Treated with a Combination Therapy of Anti-PD-1/-PD-L1 Antibodies and Platinum-Based Chemotherapy: A Multicenter Retrospective Study

Taro Hirabayashi, Kei Sonehara, Ryota Ozawa, Tsutomu Hachiya, Shuhei Nozawa, Toshihiko Agatsuma, Hiroshi Yamamoto, Akane Kato, Akemi Matsuo, Taisuke Araki, Masamichi Komatsu, Kazunari Tateishi und 1 weitere

Oncology · 2024

DOI: 10.1159/000536120 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology, 2024. Verfasst von Taro Hirabayashi und 12 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan, taroimoyamyam@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Combination therapy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibodies and platinum-based chemotherapy has been widely used as a first-line treatment for patients with unresectable advanced non-small cell lung cancer (NSCLC) in clinical settings; however, prognostic biomarkers associated with survival outcomes have not been sufficiently investigated.

Methods

We enrolled 147 previously untreated patients with advanced NSCLC who were treated with a combination therapy of anti-PD-1/-PD-L1 antibodies and platinum-based chemotherapy at eight institutions in Nagano Prefecture between December 2018 and April 2023. We evaluated the prognostic value of the geriatric nutritional risk index (GNRI), a systemic inflammatory nutritional biomarker calculated from body weight and serum albumin level, for patients with NSCLC treated with a combination therapy of anti-PD-1/-PD-L1 antibodies and platinum-based chemotherapy.

Results

The cutoff value of the GNRI was set at 92. The high GNRI and low GNRI groups included 88 and 59 patients, respectively. The median follow-up period was 15.9 months. The overall survival (OS) in the high GNRI group was significantly longer than that in the low GNRI group (27.9 vs. 15.6 months, p = 0.015). Multivariate analysis revealed that a high GNRI was an independently favorable prognostic predictor for OS (hazard ratio, 1.73; 95% confidence interval, 1.06–2.86; p = 0.031).

Conclusion

The present study demonstrates that the GNRI is a useful prognostic predictor in patients with NSCLC treated with a combination therapy of anti-PD-1/-PD-L1 antibodies and platinum-based chemotherapy in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedRetrospective StudiesPrognosisMiddle AgedAged, 80 and overB7-H1 AntigenImmune Checkpoint InhibitorsGeriatric AssessmentProgrammed Cell Death 1 ReceptorNutrition Assessment

Stichwörter der Autor:innen

Anti-programmed cell death 1/programmed cell death ligand 1 antibodiesGeriatric nutritional risk indexNon-small cell lung cancerPlatinum-based chemotherapyPrognostic predictor

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan, taroimoyamyam@gmail.com.
  • First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Respiratory Medicine, Nagano Red Cross Hospital, Nagano, Japan.
  • Department of Respiratory Medicine, Suwa Red Cross Hospital, Suwa, Japan.
  • Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Shinshu Ueda Medical Center, Ueda, Japan.

Zitieren

APA

Hirabayashi, T., Sonehara, K., Ozawa, R., Hachiya, T., Nozawa, S., Agatsuma, T., Yamamoto, H., Kato, A., Matsuo, A., Araki, T., Komatsu, M., Tateishi, K., & Hanaoka, M. (2024). Prognostic Value of the Geriatric Nutritional Risk Index in Previously Untreated Patients with Advanced Non-Small Cell Lung Cancer Treated with a Combination Therapy of Anti-PD-1/-PD-L1 Antibodies and Platinum-Based Chemotherapy: A Multicenter Retrospective Study. Oncology. https://doi.org/10.1159/000536120

Vancouver

Hirabayashi T, Sonehara K, Ozawa R, Hachiya T, Nozawa S, Agatsuma T, et al. Prognostic Value of the Geriatric Nutritional Risk Index in Previously Untreated Patients with Advanced Non-Small Cell Lung Cancer Treated with a Combination Therapy of Anti-PD-1/-PD-L1 Antibodies and Platinum-Based Chemotherapy: A Multicenter Retrospective Study. Oncology. 2024. doi:10.1159/000536120

BibTeX
@article{Hirabayashi2024,
  author = {Hirabayashi, Taro and Sonehara, Kei and Ozawa, Ryota and Hachiya, Tsutomu and Nozawa, Shuhei and Agatsuma, Toshihiko and Yamamoto, Hiroshi and Kato, Akane and Matsuo, Akemi and Araki, Taisuke and Komatsu, Masamichi and Tateishi, Kazunari and Hanaoka, Masayuki},
  title = {Prognostic Value of the Geriatric Nutritional Risk Index in Previously Untreated Patients with Advanced Non-Small Cell Lung Cancer Treated with a Combination Therapy of Anti-PD-1/-PD-L1 Antibodies and Platinum-Based Chemotherapy: A Multicenter Retrospective Study},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000536120}
}
Kostenlos starten →